STATE TIMES NEWS
Hyderabad: The supply price of Bharat Biotech’s COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.
The Centre’s supplying price is pushing the pricing structure for the private sector upward.
Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said justifying the higher price when compared to other COVID-19 vaccines available for the private sector in India.
“The supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run.
Hence a higher price in private markets is required to offset part of the costs,” it said in a statement.
Bharat Biotech has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin, it added.
Ladakh reports 33 new Covid cases
Anti-inflammation drug may effectively treat COVID-19 complications in children: Study
Apple previews new software for iPhone, other gadgets
World No Tobacco Day : Quit smoking to lead a healthy life
Rupee inches 2 paise higher at 74.27 against US dollar in early trade
India’s gold demand up 19 pc in Apr-Jun qtr at 76 tonne: WGC
Rupee surges 13 paise to 74.25 against US dollar in early trade
Gold down Rs 123, silver falls Rs 206
Rupee inches 7 paise higher to 74.35 against US dollar in early trade
Download 10Cric Casino app, and enjoy Indias most popular casino games, directly on your mobile!
Gamble with real money online! Play Indias favourite casino games at 7Jackpots.com, Indias most trusted online casino site.
© 2020 State Times Daily Newspaper | Powered by Ideogram Technology Solutions [P] Ltd.